
APCOM welcomes the landmark agreement brokered by CHAI and UNITAID, which provides Dr. Reddy’s Laboratories with financial, technical, and regulatory support to deliver affordable, quality-assured generic versions of lenacapavir to low- and middle-income countries by 2027.
We also applaud the newly announced partnership between the Gates Foundation and Indian manufacturer Hetero Labs, backed by upfront funding and volume guarantees, to produce generic lenacapavir at an estimated $40 per patient per year—a price point that brings this breakthrough prevention option within reach of national health systems.
These strategic investments, alongside the Gates Foundation’s catalytic commitment of over $80 million, represent a critical acceleration in market readiness, delivery scale-up, and the timeline for generic entry. They respond directly to long-standing demands from communities for equitable access to the most advanced HIV prevention tools.
Lenacapavir, a twice-yearly injectable pre-exposure prophylaxis (PrEP), offers a powerful new option for people who face barriers to daily oral PrEP, including stigma, adherence challenges, and inconsistent access.
In the Asia-Pacific region, access to HIV prevention remains deeply unequal. While oral PrEP has been available for over a decade, uptake is still limited especially among key populations. In 2024, Asia-Pacific accounted for an estimated 260,000 new HIV infections, with young people and marginalized communities disproportionately affected. The introduction of long-acting injectable PrEP, such as lenacapavir, offers a transformative opportunity to close this prevention gap.
We commend the strategic coordination across global and national actors, including CHAI, UNITAID, the Gates Foundation, Gilead Sciences, and generic manufacturers, for responding to community demands with speed, transparency, and resolve. This is a critical step toward ending the epidemic faster and more equitably.
These global moves signal progress. But progress must be matched by political will and domestic investment. Governments must prioritize HIV prevention in national budgets, and ensure that long-acting PrEP is integrated into public health systems in ways that are community-led, stigma-free, and responsive to local realities.
As we celebrate these advances, APCOM calls for sustained support for community leadership and community-led service providers. We urge all stakeholders to address the legal and policy barriers that continue to block access. Only then will generic long-acting injectable PrEP be truly affordable, available, and accessible to those who need it most.

From 5 to 7 November 2025 in Bangkok, APCOM will convene the APCOM Community Summit: PrEPARING ASIA 2025, a follow on from its groundbreaking PrEPARING Asia 2015, a decade ago. This Summit will bring together governments, technical agencies, researchers, funders and community representatives to consolidate regional strategies that protect and build on the progress made in prevention, securing the future of the HIV response.
Key outcomes of the Summit will include a Regional Advocacy Statement that reaffirms the leadership of people living with HIV and key populations, a financing roadmap for the sustainable scale-up of PrEP, and high-level roundtables with UNAIDS, WHO, the Global Fund, governments and regional networks to secure commitments for the period 2026-2030.
These deliberations are designed to ensure that Asia Pacific voices inform the UN80 process and that any reforms do not derail, but rather reinforce, the regional HIV response.
Further reading:
UNAIDS welcomes the announcement of new deals to make new HIV prevention medicines available and affordable for people in need
APCOM and HIV Prevention:
APCOM is a member of The Global Prevention Coalition (GPC), a coalition of UN Member States and partners, was established to accelerate global HIV prevention efforts by supporting national policy-makers and programme managers to achieve the target of having 95% of people at risk of HIV accessing effective prevention options. Supported by UNAIDS, the GPC includes numerous focus countries that have seen significant reductions in new HIV infections, highlighting the coalition’s role in a transformed, sustainable, and inclusive response to the HIV epidemic.
APCOM is a representative from Asia of the Civil Society Caucus on Long-Acting PrEP coordinated by AVAC, which feeds into the Coalition to Accelerate Access to Long-Acting PrEP brings together donors, civil society, ministries of health, implementation science think tanks and partner organizations to ensure an accelerated, equitable, sustainable, and collaborative approach to optimizing access to new long-acting PrEP options. The Coalition is convened by the Global Fund, PEPFAR, Unitaid, UNAIDS and WHO, with AVAC as the Secretariat. The Coalition’s objective is to coordinate key stakeholder activities on long-acting PrEP access, including jointly developing strategies to identify and overcome access challenges for new PrEP options available now and those in the pipeline.


